Status:
COMPLETED
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
Lead Sponsor:
Novartis
Conditions:
Bipolar I Disorder
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6-week double-blind study CLIC477D2302.
Eligibility Criteria
Inclusion
- written informed consent provided prior to participation in the extension study.
- successful completion of the study CLIC477D2302
- willingness and ability to comply with all study requirements
Exclusion
- premature discontinuation from the study CLIC477D2302
- failure to comply with the study CLIC477D2302 protocol
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
251 Patients enrolled
Trial Details
Trial ID
NCT00238485
Start Date
January 1 2005
End Date
July 1 2007
Last Update
March 28 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.